Jazz Pharmaceuticals Public Limited Company (JAZZ)

In the past six months, Jazz Pharmaceuticals Plc stock price has seen significant movement. As of November 25, 2025, the share price was $180.05, representing an increase of 46.63% from November 26, 2024. Over the last six months, the stock has risen by 64.27%. Key events impacting the stock include Q2 2025 financial results and updated 2025 financial guidance, positive Phase 3 trial results for Ziihera, presentation of Modeyso data, participation in Citi's 2025 Global Healthcare Conference, the sale of the Sativex business, regulatory approvals for Ziihera and Zepzelca, and analyst ratings and price target adjustments.

The provided search results do not contain specific information regarding the demand seasonality for Jazz Pharmaceuticals Plc's products and services. Pharmaceutical demand can sometimes be influenced by factors such as seasonal illnesses, but without direct data, it is not possible to determine specific seasonality for Jazz Pharmaceuticals' product portfolio.

Jazz Pharmaceuticals Plc is a global biopharmaceutical company focused on developing and commercializing innovative medicines for serious diseases with limited treatment options. The company operates in the biotechnology and pharmaceutical sectors, specifically in the "Pharmaceuticals: Major" industry. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals was founded in 2003 in California, U.S. The company's core business segments are neuroscience and oncology. Its major marketed products include Xyrem and Xywav for narcolepsy and idiopathic hypersomnia, Epidiolex/Epidyolex for severe epilepsy syndromes, Rylaze/Enrylaze for acute lymphoblastic leukemia and lymphoblastic lymphoma, Zepzelca for metastatic small cell lung cancer, Vyxeos for adults with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes, Defitelio, Sunosi for improving wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea, and Sativex, which was sold to CNX Therapeutics in November 2025.

Jazz Pharmaceuticals has a global commercial and operational footprint with medicines available in nearly 100 countries. The company has a direct commercial and operational presence in Europe, North America, and Australia, and is expanding into Japan. They also partner with other companies to bring their medicines to patients in regions such as Asia Pacific and Latin America. Jazz Pharmaceuticals operates world-class facilities, including manufacturing centers, in the U.S., U.K., Ireland, and throughout Europe. The company has a significant corporate presence in Palo Alto, CA, Philadelphia, PA, and in England in London, Oxford, and Cambridge.

Jazz Pharmaceuticals aims to improve patients' lives by developing and commercializing medicines for serious diseases. The company emphasizes its commitment to innovation and patient care, positioning itself as a trusted name in the biopharmaceutical sector. Events affecting the company's reputation include positive clinical trial results and regulatory approvals, presentations of new data, and the appointment of Renée Gala as President and CEO. Historical legal issues related to Xyrem are also part of the company's record.

Jazz Pharmaceuticals Plc is primarily owned by institutional shareholders, with approximately 75.87% of the company's stock held by Institutional Investors, 3.64% by Insiders, and 20.49% by Public Companies and Individual Investors. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Dimensional Fund Advisors Lp. KKR Group Partnership LP is the largest individual shareholder, owning 50.33% of the company. Insiders have been net sellers recently, with directors and executives selling shares valued at approximately $8.56 million over the past 90 days.